2. Anti-infection
  3. Bacterial
  4. Olamufloxacin

Olamufloxacin (HSR-903) is an orally active fluoroquinolone antibacterial agent. Olamufloxacin inhibits DNA supercoiling activity. Olamufloxacin exhibits activity against Gram-positive, Gram-negative, chlamydial, and quinolone-resistant bacterial strains. Olamufloxacin can be used for the research of bacterial infections.

For research use only. We do not sell to patients.

Olamufloxacin

Olamufloxacin Chemical Structure

CAS No. : 167887-97-0

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Olamufloxacin Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Olamufloxacin (HSR-903) is an orally active fluoroquinolone antibacterial agent. Olamufloxacin inhibits DNA supercoiling activity. Olamufloxacin exhibits activity against Gram-positive, Gram-negative, chlamydial, and quinolone-resistant bacterial strains. Olamufloxacin can be used for the research of bacterial infections[1][2][3][4][5].

In Vitro

Olamufloxacin demonstrates potent antimicrobial activity against Gram-positive and Gram-negative clinical bacterial isolates, with MIC50-like MICs ranging from 0.008 mg/L to 0.25 mg/L depending on the strain[1].
Olamufloxacin (18-42 h) potently inhibits growth of gram-positive bacterial clinical isolates including MSSA (MIC90 = 0.78 μg/mL), MRSA (MIC90 = 1.56 μg/mL), PSSP (MIC90 = 0.05 μg/mL), and PRSP (MIC90 = 0.05 μg/mL)[2].
Olamufloxacin (1/4×-2× MIC; 4 h) demonstrates rapid bactericidal activity against S. aureus Smith, E. coli KC-14, and P. aeruginosa E-2[2].
Olamufloxacin potently inhibits E. coli KL-16 DNA gyrase (IC50 = 0.74 μg/mL) but shows weak activity against human placental topoisomerase II (IC50 = 786 μg/mL)[2].
Olamufloxacin (48-72 h) potently inhibits growth of Chlamydia psittaci, Chlamydia trachomatis, and Chlamydia pneumoniae in infected HeLa 229 cells with MICs ranging from 0.016 to 0.063 μg/mL[4].
Olamufloxacin (24 h) potently inhibits growth of clinical Neisseria gonorrhoeae isolates, including those with quinolone resistance-associated alterations in GyrA and ParC[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Olamufloxacin Related Antibodies
Parmacokinetics
Species Dose Route T1/2 Cmax AUC0-∞ (Plasma)
Mice[3] 50 mg/kg p.o. 2.83 h 1.42 μg/mL 6.67 μg·h/mL
In Vivo

Olamufloxacin (3.13-50 mg/kg; p.o.; twice daily; 3 days) demonstrates activity against P. aeruginosa-induced UTI in mice[1].
Olamufloxacin (50 mg/kg; p.o.; three times daily; 3 days) effectively reduces lung bacterial burden in mice with Penicillin-resistant S. pneumoniae pneumonia[3].
Olamufloxacin (0.625 mg/kg; p.o.; twice daily; 3 days) demonstrates potent activity against H. influenzae respiratory tract infection in ICR mice[3].
Olamufloxacin (5-10 mg/kg; p.o.; twice daily; 5 days) exhibits in vivo efficacy in mice with Chlamydia psittaci-induced pneumonia[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: slc:ICR mice (4-week-old female, 15-19 g) with UTI caused by P. aeruginosa[1]
Dosage: 3.13; 12.5; 50 mg/kg
Administration: p.o.; twice daily; 3 days
Result: Resulted in 10/10 survival and a mean log cfu/kidneys count of 1.41 at 50 mg/kg.
Resulted in 9/10 survival and a mean log cfu/kidneys count of 2.72 at 12.5 mg/kg.
Resulted in 6/15 survival and a mean log cfu/kidneys count of 5.82 at 3.13 mg/kg, with no significant reduction versus control.
Animal Model: CBA/J mice (4-week-old, 15-22 g weight) with pneumonia caused by Penicillin-resistant Streptococcus pneumoniae TUM741[3]
Dosage: 50 mg/kg
Administration: p.o.; three times daily; 3 days
Result: Reduced mean lung viable bacterial counts to 3.8 log CFU.
Achieved a 14-day survival rate of 50%.
Animal Model: ICR mice (4-week-old male, ~20 g weight) with respiratory tract infection caused by Haemophilus influenzae TMS8[3]
Dosage: 0.625 mg/kg
Administration: p.o.; twice daily; 3 days
Result: Significantly reduced viable bacterial counts in the lower respiratory tract at all time points post-drug administration.
Animal Model: ICR mice (5-week-old male) with pneumonia caused by Chlamydia psittaci[4]
Dosage: 5; 10 mg/kg
Administration: p.o.; twice daily; 5 days
Result: Achieved a 100% survival rate at day 14 post-infection.
Showed significantly higher or longer survival rates.
Molecular Weight

386.43

Formula

C20H23FN4O3
CAS No.
SMILES

N[C@H]1C2(CN(C1)C=3C(C)=C4N(C=C(C(O)=O)C(=O)C4=C(N)C3F)C5CC5)CC2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Olamufloxacin Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Olamufloxacin167887-97-0HSR-903HSR903HSR 903BacterialEnterobacteriaceaeChlamydia trachomatisEscherichia coli DNA gyraseHelicobacter pyloriChlamydia psittaciNeisseria gonorrhoeaehuman topoisomerase IIHeLa 229 cellsHaemophilus influenzaeStreptococcus pneumoniaeInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Olamufloxacin
Cat. No.:
HY-W683763
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.